A Randomized, Double-blind, Placebo-controlled, Multicenter Long-term Safety and Tolerability Study of ETC-1002 in Patients With Hyperlipidemia at High Cardiovascular Risk Who Are Not Adequately Controlled by Their Lipid-Modifying Therapy
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Nov 2017
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Acronyms CLEAR Harmony
- Sponsors Esperion Therapeutics
- 10 Jun 2017 Biomarkers information updated
- 20 Mar 2017 According to an Esperion Therapeutics media release, top-line results from this study are expected by Q2 2018.
- 20 Mar 2017 According to an Esperion Therapeutics media release, top-line results expected by Q2 2018.